PDL Biopharma Inc., of Incline Village, Nev., said it has amended a royalty purchase and sale agreement with Newark, Calif.-based Depomed Inc. As a result, it has acquired all of Depomed's remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by the firm for up to $20 million.